Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

HIV-1 superinfection in a patient with known HIV-2 - A case report.

Ring K, Muir D, Mackie N, Bailey AC.

Int J STD AIDS. 2020 Feb 2:956462420901969. doi: 10.1177/0956462420901969. [Epub ahead of print] No abstract available.

PMID:
32009569
2.

Characterization of low level viraemia in HIV-infected patients receiving boosted protease inhibitor-based antiretroviral regimens.

Ferretti F, Mackie NE, Singh GKJ, Fox J, Kaye S, McClure MO, Taylor G, Boffito M.

HIV Res Clin Pract. 2019 Aug - Oct;20(4-5):107-110. doi: 10.1080/25787489.2020.1716159. Epub 2020 Jan 30.

PMID:
32000615
3.

Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.

Stirrup OT, Asboe D, Pozniak A, Sabin CA, Gilson R, Mackie NE, Tostevin A, Hill T, Dunn DT; UK HIV Drug Resistance Database and the UK Collaborative HIV Cohort.

HIV Med. 2020 Jan 11. doi: 10.1111/hiv.12829. [Epub ahead of print]

PMID:
31927793
4.

Compromised CD4:CD8 ratio recovery in people living with HIV aged over 50 years: an observational study.

Francis-Morris A, Mackie NE, Eliahoo J, Ramzan F, Fidler S, Pollock KM.

HIV Med. 2020 Feb;21(2):109-118. doi: 10.1111/hiv.12800. Epub 2019 Oct 16.

5.

Association of HIV status with sexual function in women aged 45-60 in England: results from two national surveys.

Toorabally N, Mercer CH, Mitchell KR, Blell M, Burns F, Gilson R, McGregor-Read J, Allan S, De Ruiter A, Dhairyawan R, Fox J, Gilleece Y, Jones R, Mackie N, Obeyesekera S, Post F, Reeves I, Rosenvinge M, Ross J, Sarner L, Sullivan A, Tariq A, Ustianowski A, Sabin CA, Tariq S.

AIDS Care. 2020 Mar;32(3):286-295. doi: 10.1080/09540121.2019.1653436. Epub 2019 Aug 14.

PMID:
31411046
6.

Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009-2018.

Abo YN, Refsum E, Mackie N, Lyall H, Tudor-Williams G, Foster C.

Clin Drug Investig. 2019 Jun;39(6):585-590. doi: 10.1007/s40261-019-00783-8.

PMID:
30976998
7.

Reasons for delayed antiretroviral therapy (ART) initiation in the era of early ART initiation guidelines: a retrospective service evaluation.

Lee MJ, Venturelli S, McKenna W, Teh J, Negedu O, Florman KE, Musbahi E, Bailey AC, Mackie NE, Fox J, Fidler S.

Int J STD AIDS. 2019 Mar;30(4):415-418. doi: 10.1177/0956462418814985. Epub 2019 Jan 8.

PMID:
30621548
8.

The association between detected drug resistance mutations and CD4+ T-cell decline in HIV-positive individuals maintained on a failing treatment regimen.

Schultze A, Paredes R, Sabin C, Phillips AN, Pillay D, Mackie N, Castagna A, Chadwick D, Falconer K, Geretti AM, Post FA, Hill T, Kirk O, Pozniak A, Nelson M, Tostevin A, Dunn D, Lundgren J, Cozzi-Lepri A.

Antivir Ther. 2018;23(2):105-116. doi: 10.3851/IMP3178.

PMID:
28627486
9.

Retrospective review of routine clinical patient experiences with dolutegravir; virological suppression, immunological recovery and adverse events.

Negedu O, Kim SH, Weston R, Naous N, Mackie N, Fidler S.

HIV Med. 2017 Oct;18(9):709-710. doi: 10.1111/hiv.12510. Epub 2017 Apr 26. No abstract available.

10.

Off-licence use of once-daily maraviroc in children and adolescents with perinatally acquired HIV-1 infection.

Fraser-Taliente T, Mackie NE, Kaye S, Nyirenda M, Foster C.

HIV Med. 2017 Apr;18(4):311-313. doi: 10.1111/hiv.12467. Epub 2016 Dec 16. No abstract available.

11.

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A, Pillay D, Dunn DT; UK HIV Drug Resistance Database; (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees; UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Steering Committees.

J Antimicrob Chemother. 2016 Dec;71(12):3487-3494. Epub 2016 Sep 28.

12.

Scald Burn Injuries Caused by Showers Among the Adult Population in the Southwest Region.

Emam A, Mackie N, Mackie I.

J Burn Care Res. 2017 Jul/Aug;38(4):e781. doi: 10.1097/BCR.0000000000000419. No abstract available.

PMID:
27606552
13.

British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015.

Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S, Emerson C, Fidler S, Fisher M, Horne R, Khoo S, Leen C, Mackie N, Marshall N, Monteiro F, Nelson M, Orkin C, Palfreeman A, Pett S, Phillips A, Post F, Pozniak A, Reeves I, Sabin C, Trevelion R, Walsh J, Wilkins E, Williams I, Winston A.

HIV Med. 2016 Aug;17 Suppl 4:s2-s104. doi: 10.1111/hiv.12426. No abstract available.

14.

An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis.

Dolling DI, Desai M, McOwan A, Gilson R, Clarke A, Fisher M, Schembri G, Sullivan AK, Mackie N, Reeves I, Portman M, Saunders J, Fox J, Bayley J, Brady M, Bowman C, Lacey CJ, Taylor S, White D, Antonucci S, Gafos M, McCormack S, Gill ON, Dunn DT, Nardone A; PROUD Study Group.

Trials. 2016 Mar 24;17:163. doi: 10.1186/s13063-016-1286-4.

15.

Clinical characteristics and outcomes of HIV-associated immune complex kidney disease.

Booth JW, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar EA, Turner-Stokes T, Khatib N, Das P, Naftalin C, Mackie N, Kingdon E, Williams D, Hendry BM, Sabin C, Jones R, Levy J, Hilton R, Connolly J, Post FA; HIV/CKD Study and the UK CHIC Study.

Nephrol Dial Transplant. 2016 Dec;31(12):2099-2107. Epub 2016 Jan 18.

PMID:
26786550
16.

Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.

McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G, Mackie N, Bowman C, Lacey CJ, Apea V, Brady M, Fox J, Taylor S, Antonucci S, Khoo SH, Rooney J, Nardone A, Fisher M, McOwan A, Phillips AN, Johnson AM, Gazzard B, Gill ON.

Lancet. 2016 Jan 2;387(10013):53-60. doi: 10.1016/S0140-6736(15)00056-2. Epub 2015 Sep 9.

17.

Virtual support for paediatric HIV treatment decision making.

Le Doare K, Mackie NE, Kaye S, Bamford A, Walters S, Foster C.

Arch Dis Child. 2015 Jun;100(6):527-31. doi: 10.1136/archdischild-2014-307019. Epub 2014 Dec 30.

19.

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK.

El Bouzidi K, White E, Mbisa JL, Phillips A, Mackie N, Pozniak A, Dunn D.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19739. doi: 10.7448/IAS.17.4.19739. eCollection 2014.

20.

Service impact of a change in HIV-1 viral load quantification assay.

Tipple C, Oomeer S, Dosekun O, Mackie N.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19677. doi: 10.7448/IAS.17.4.19677. eCollection 2014.

21.

End-stage kidney disease and kidney transplantation in HIV-positive patients: an observational cohort study.

Gathogo E, Jose S, Jones R, Levy JB, Mackie NE, Booth J, Connolly J, Johnson M, Leen C, Williams D, Sabin CA, Post FA.

J Acquir Immune Defic Syndr. 2014 Oct 1;67(2):177-80. doi: 10.1097/QAI.0000000000000291.

PMID:
25072607
22.

Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy.

Mora-Peris B, Watson V, Vera JH, Weston R, Waldman AD, Kaye S, Khoo S, Mackie NE, Back D, Winston A.

J Antimicrob Chemother. 2014 Jun;69(6):1642-7. doi: 10.1093/jac/dku018. Epub 2014 Feb 11.

PMID:
24521854
23.

Can Archival Tissue Reveal Answers to Modern Research Questions?: Computer-Aided Histological Assessment of Neuroblastoma Tumours Collected over 60 Years.

Chetcuti A, Mackie N, Tafavogh S, Graf N, Henwood T, Charlton A, Catchpoole D.

Microarrays (Basel). 2014 Feb 28;3(1):72-88. doi: 10.3390/microarrays3010072.

24.

Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression.

O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M, Ainsworth J, Gilson R, Mackie N, Anderson J, Orkin C, Nelson M, Kegg S, Leen C, Palfreeman A, Post F, Johnson M, Sabin CA, Phillips AN; UK Collaborative HIV Cohort (UK CHIC) Study Steering Committee.

AIDS. 2014 Mar 27;28(6):919-24. doi: 10.1097/QAD.0000000000000165.

PMID:
24335482
25.

The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.

Mackie NE, Dunn DT, Dolling D, Garvey L, Harrison L, Fearnhill E, Tilston P, Sabin C, Geretti AM; UK HIV Drug Resistance Database; UK CHIC study.

AIDS. 2013 Sep 10;27(14):2245-53. doi: 10.1097/QAD.0b013e3283636179.

PMID:
24157905
26.

Raltegravir resistance in the cerebrospinal fluid.

Mora-Peris B, Mackie NE, Suan D, Cooper DA, Brew BJ, Winston A.

Infection. 2013 Jun;41(3):731-4. doi: 10.1007/s15010-013-0409-z. Epub 2013 Feb 3.

PMID:
23378293
27.

The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype.

Vera JH, Naous N, Mackie N, Winston A, Cooke G.

AIDS. 2013 Jan 28;27(3):484-5. doi: 10.1097/QAD.0b013e32835a9a0d.

PMID:
23032409
28.

Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study.

UK Collaborative Group on HIV Drug Resistance, Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown AL, Churchill D, Williams I, Geretti AM, Phillips A, Mackie N, Murphy G, Castro H, Pillay D, Cane P, Dunn D, Dolling D.

BMJ. 2012 Aug 21;345:e5253. doi: 10.1136/bmj.e5253.

29.

Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting.

Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A.

J Infect. 2012 Sep;65(3):239-45. doi: 10.1016/j.jinf.2012.04.007. Epub 2012 Apr 17.

PMID:
22522289
30.

Hemodiafiltration with online regeneration of ultrafiltrate for severe nevirapine intoxication in a HIV-infected patient.

Hougardy JM, Husson C, Mackie NE, Van Vooren JP, Gastaldello K, Nortier JL, Goffard JC.

AIDS. 2012 Mar 13;26(5):653-5. doi: 10.1097/QAD.0b013e3283509770. No abstract available.

PMID:
22398572
31.

Increased levels of CD4 T-cell activation in individuals with CXCR4 using viruses in primary HIV-1 infection.

Hamlyn E, Hickling S, Porter K, Frater J, Phillips R, Robinson M, Mackie NE, Kaye S, McClure M, Fidler S; SPARTAC Investigators.

AIDS. 2012 Apr 24;26(7):887-90. doi: 10.1097/QAD.0b013e328351e721.

PMID:
22313951
32.

British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011.

Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P, Mackie N, Muir D, Murphy G, Orkin C, Post F, Rooney G, Sabin C, Sherr L, Smit E, Tong W, Ustianowski A, Valappil M, Walsh J, Williams M, Yirrell D; BHIVA Guidelines Subcommittee.

HIV Med. 2012 Jan;13(1):1-44. doi: 10.1111/j.1468-1293.2011.00971.x. No abstract available.

33.

Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study.

Prosperi MC, Mackie N, Di Giambenedetto S, Zazzi M, Camacho R, Fanti I, Torti C, Sönnerborg A, Kaiser R, Codoñer FM, Van Laethem K, Bansi L, van de Vijver DA, Geretti AM, De Luca A; SEHERE consortium.

J Antimicrob Chemother. 2011 Aug;66(8):1886-96. doi: 10.1093/jac/dkr171. Epub 2011 May 30.

PMID:
21624929
34.

Expression profiling reveals MSX1 and EphB2 expression correlates with the invasion capacity of Wilms tumors.

Chetcuti A, Aktas S, Mackie N, Ulger C, Toruner G, Alkan M, Catchpoole D.

Pediatr Blood Cancer. 2011 Dec 1;57(6):950-7. doi: 10.1002/pbc.23003. Epub 2011 Mar 8.

PMID:
21387540
35.

The impact of HIV drug resistance testing on changes to treatment.

Bansi L, Smith C, Phillips A, Kirk S, Geretti AM, Johnson M, Mackie N, Post F, Gazzard B, Dunn D, Sabin C; UK Collaborative HIV Cohort (CHIC) Study and the UK Collaborative Group on HIV Drug Resistance (HDRD).

AIDS. 2011 Mar 13;25(5):603-10. doi: 10.1097/QAD.0b013e32834403a0.

PMID:
21297420
36.

Resistance to non-nucleoside reverse transcriptase inhibitors.

Mackie N.

In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 2.

37.

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment.

Vandekerckhove L, Verhofstede C, Demecheleer E, De Wit S, Florence E, Fransen K, Moutschen M, Mostmans W, Kabeya K, Mackie N, Plum J, Vaira D, Van Baelen K, Vandenbroucke I, Van Eygen V, Van Marck H, Vogelaers D, Geretti AM, Stuyver LJ.

J Antimicrob Chemother. 2011 Feb;66(2):265-72. doi: 10.1093/jac/dkq458. Epub 2010 Dec 31.

38.

Tape transfer sectioning of tissue microarrays introduces nonspecific immunohistochemical staining artifacts.

Catchpoole D, Mackie N, McIver S, Chetcuti A, Henwood A, Graf N, Arbuckle S.

Biotech Histochem. 2011 Dec;86(6):421-8. doi: 10.3109/10520295.2010.527859. Epub 2010 Nov 22.

PMID:
21091080
39.

The effects of a nucleoside-sparing antiretroviral regimen on the pharmacokinetics of ritonavir-boosted darunavir in HIV type-1-infected patients.

Garvey L, Latch N, Erlwein OW, Mackie NE, Walsh J, Scullard G, McClure MO, Dickinson L, Back D, Winston A.

Antivir Ther. 2010;15(2):213-8. doi: 10.3851/IMP1517.

PMID:
20386076
40.

Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia.

Mackie NE, Phillips AN, Kaye S, Booth C, Geretti AM.

J Infect Dis. 2010 May 1;201(9):1303-7. doi: 10.1086/651618.

PMID:
20350161
41.

Clinical epidemiology of HIV-associated end-stage renal failure in the UK.

Bansi L, Hughes A, Bhagani S, Mackie NE, Leen C, Levy J, Edwards S, Connolly J, Holt SG, Hendry BM, Sabin C, Post FA; UK CHIC/ESRF study group.

AIDS. 2009 Nov 27;23(18):2517-21. doi: 10.1097/QAD.0b013e3283320e12.

PMID:
19752713
42.

Detectable cerebrospinal fluid HIV RNA with associated neurological deficits, despite suppression of HIV replication in the plasma compartment.

Garvey LJ, Everitt A, Winston A, Mackie NE, Benzie A.

AIDS. 2009 Jul 17;23(11):1443-4. doi: 10.1097/QAD.0b013e32832d077c. No abstract available.

PMID:
19564723
43.

The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.

Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C, Gazzard B, Porter K, Mackie N, Fisher M, Orkin C, Johnson M, Easterbrook P, Hill T, Phillips AN; UK Collaborative HIV Cohort (CHIC) Study.

HIV Med. 2009 Jan;10(1):35-43. doi: 10.1111/j.1468-1293.2008.00654.x. Epub 2008 Nov 10.

44.

British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008.

Fakoya A, Lamba H, Mackie N, Nandwani R, Brown A, Bernard E, Gilling-Smith C, Lacey C, Sherr L, Claydon P, Wallage S, Gazzard B.

HIV Med. 2008 Oct;9(9):681-720. doi: 10.1111/j.1468-1293.2008.00634.x. No abstract available.

45.

Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers.

Guimarães-Walker A, Mackie N, McCormack S, Hanke T, Schmidt C, Gilmour J, Barin B, McMichael A, Weber J, Legg K, Babiker A, Hayes P, Gotch F, Smith C, Dally L, Dorrell L, Cebere I, Kay R, Winstone N, Moore S, Goonetilleke N, Fast P; IAVI-006 Study Group.

Vaccine. 2008 Dec 2;26(51):6671-7. doi: 10.1016/j.vaccine.2008.09.016. Erratum in: Vaccine. 2011 Apr 18;29(18):3511.

PMID:
18812202
46.

Participation in two phase II prophylactic HIV vaccine trials in the UK.

Gray K, Legg K, Sharp A, Mackie N, Olarinde F, De Souza C, Weber J, Peters B.

Vaccine. 2008 Jun 2;26(23):2919-24. doi: 10.1016/j.vaccine.2008.03.039. Epub 2008 Apr 9.

PMID:
18450339
47.

High treatment success rates when switching to once daily nevirapine containing antiretroviral therapy.

Benzie A, Marett B, Mackie NE, Winston A.

Open AIDS J. 2008;2:89-93. doi: 10.2174/1874613600802010089. Epub 2008 Dec 18.

48.

Polymorphisms at position 245 of HIV reverse transcriptase do not accurately predict the presence of human leukocyte antigen B*5701.

Waters LJ, Mackie NE, Pozniak A, Winston A.

Clin Infect Dis. 2007 Nov 1;45(9):1243-4; author reply 1244-5. No abstract available.

PMID:
17918094
49.

Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?

Barber TJ, Marett B, Waldron S, Portsmouth S, Mackie NE, Weston R, Winston A.

AIDS. 2007 Aug 20;21(13):1823-4.

PMID:
17690585
50.

Prevalence of primary genotypic resistance in a UK centre: Comparison of primary HIV-1 and newly diagnosed treatment-naive individuals.

Fox J, Hill S, Kaye S, Dustan S, McClure M, Fidler S, Mackie NE.

AIDS. 2007 Jan 11;21(2):237-9.

PMID:
17197816

Supplemental Content

Loading ...
Support Center